Singapore markets closed
Straits Times Index
3,204.82 +2.01 (+0.06%) Nikkei
32,402.41 -168.62 (-0.52%) Hang Seng
18,057.45 +402.04 (+2.28%) FTSE 100
7,683.91 +5.29 (+0.07%) Bitcoin USD
26,569.06 +15.78 (+0.06%) CMC Crypto 200
565.87 -2.18 (-0.38%)
FibroGen, Inc. (0IL8.L)
LSE - LSE Delayed Price. Currency in USD
Add to watchlist
At close: 07:13PM BST
| Previous close | 0.8464 |
| Open | 0.8452 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.7759 - 0.8547 |
| 52-week range | 0.7055 - 25.1300 |
| Volume | |
| Avg. volume | 30,157 |
| Market cap | 551,480 |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.0370 |
| Earnings date | 06 Nov 2023 - 10 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksBiotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More
Regulatory updates from Fibrogen (FGEN) and Bristol Myers (BMY) are in focus in the biotech sector.
ZacksFibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23%
FibroGen (FGEN) falls 22.7% as its late-stage study of pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy fails to meet the primary endpoint.
ZacksDown -46.88% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for FibroGen (FGEN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
© 2023 Yahoo. All rights reserved.
